Immunic

IMUX

Capitalización de mercado USD 95.1 M

Immunic Inc (NASDAQ:IMUX, FRA:10VA) said four abstracts on its lead MS drug candidate, vidofludimus calcium, have been accepted for presentation at the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto from October 21 to 23.  The oral therapy is a Nurr1 activator under development for neurologic diseases.

– Four Accepted Abstracts Further Characterize Investigational Vidofludimus Calcium's Profile in Multiple Sclerosis Across Long-Term Disability Outcomes, EBV-Related Immune Activity and Cognition, Novel Disability Measurement, and Nurr1-Mediated Neuronal Survival – – New Phase 2 CALLIPER Open-Label Extension Data Show Disability Outcomes Favoring Continuous Vidofludimus Calcium Treatment Maintained Through Extension Week 48, With Low Treatment Discontinuation – NEW YORK, Oct. 7, 2026 /PRNewswire/ -- Immunic , Inc.  (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that four abstracts highlighting new clinical, biomarker and preclinical data for its lead investigational asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), have been accepted for presentation at MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting, taking place October 21-23, 2026, in Toronto, Canada. All accepted abstracts will be published in the online supplement of the Multiple Sclerosis Journal and made available through the MSToronto2026 website, event app, and digital platform.

Immunic, Inc. (IMUX) Discusses R&D Advances and Future Directions in Relapsing Multiple Sclerosis Transcript

Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced that it will host a virtual research and development day focused on relapsing multiple sclerosis on September 9, as the biotechnology company prepares for topline results from its Phase 3 ENSURE trials expected by the end of 2026. The event will feature Immunic management, including CEO Erik Lundgren, chief medical officer Michael Panzara, chief scientific officer Hella Kohlhof and president and chief operating officer Jason Tardio.

NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it will host a virtual research and development (R&D) day focused on relapsing multiple sclerosis (MS) on Wednesday, September 9, 2026, at 11:00 am ET.

– New C-Suite Role and Appointment Underscore Commitment to Building a Strong, Commercial-Ready Data Ecosystem, in Preparation for Potential NDA Submission and Commercialization – NEW YORK, Sept. 1, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Chitrang Davé as Chief Data and Digital Officer (CDDO), effective today.

Immunic is advancing vidofludimus calcium (IMU-838) in late-stage trials for both relapsing and progressive multiple sclerosis. MS represents a substantial market, with existing therapies projected to reach ~$22 billion in 2026 revenues. IMU-838's oral administration and differentiated mechanism of action position it as a potential major player in the MS market.

The mean of analysts' price targets for Immunic (IMUX) points to a 163% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Immunic Inc (NASDAQ:IMUX, FRA:10VA) is preparing for a series of clinical and corporate milestones as it advances its lead drug candidate vidofludimus calcium through late-stage development in multiple sclerosis, while expanding its leadership team ahead of potential regulatory filings and commercialization. The biotechnology company reported second-quarter results on Tuesday and said its Phase 3 ENSURE-1 and ENSURE-2 trials evaluating vidofludimus calcium in relapsing multiple sclerosis remain on track to deliver top-line data by the end of 2026.

– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial Readiness – – Pivotal Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis on Track, with Top-Line Data Expected by End of 2026 – – Continued Preparations for Phase 3 Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis, with Initiation Planned Later This Year – NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Immunic , Inc.  (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. "During the second quarter, we continued to execute across our late-stage development priorities as we advance toward what we believe will be a transformational period for Immunic," said Erik Lundgren, Chief Executive Officer of Immunic.